Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Csl Behring Gmbh patents


Recent patent applications related to Csl Behring Gmbh. Csl Behring Gmbh is listed as an Agent/Assignee. Note: Csl Behring Gmbh may have other listings under different names/spellings. We're not affiliated with Csl Behring Gmbh, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "C" | Csl Behring Gmbh-related inventors


Pharmaceutical formulations of c1 esterase inhibitor

The present invention relates to pharmaceutical formulations comprising the C1 esterase inhibitor (“C1-INH”), exhibiting a higher stability for prolonged storage and a reduced kinematic viscosity for ameliorated use in treating or preventing disorders related to kinin formation.... Csl Behring Gmbh

Sugar compositions for treating hemophilia a and/or von willebrand disease

The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.... Csl Behring Gmbh

Improved factor viii preparations suitable for therapeutic use and processes to obtain these

The present invention relates to pharmaceutical preparations comprising two-chain Factor VIII that are essentially free of Factor VIII-Light Chains (FVIII-LCs) which are not associated with Factor VIII-Heavy Chains (FVIII-HCs) having higher purity and which are less immunogenic. The invention also relates to methods to test the suitability of a pharmaceutical... Csl Behring Gmbh

Method of purifying therapeutic proteins

Also provided are solutions and pharmaceutical formulations comprising the fibrinogen and/or Factor VIII and/or VWF recovered by such methods, and uses thereof.... Csl Behring Gmbh

Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses

The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.... Csl Behring Gmbh

Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses

The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.... Csl Behring Gmbh

Therapy using a factor xii inhibitor in a neurotraumatic disorder

The present invention relates to the use of a direct Factor XII (FXII) inhibitor in the treatment of a neurotraumatic disorder resulting from a traumatic injury of the brain (traumatic brain injury, TBI) or the spinal cord (spinal cord injury, SCI).... Csl Behring Gmbh

Modified coagulation factor viia with extended half-life

The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked... Csl Behring Gmbh








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Csl Behring Gmbh in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Csl Behring Gmbh with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###